Enrollment of Older Patients in Cancer Treatment Trials in Canada: Why is Age a Barrier?
To evaluate the enrollment of older patients (>/= 65 years) in Canadian cancer treatment trials and compare accrual of older patients in Canada and the United States. A retrospective analysis of the number of older patients enrolled in National Cancer Institute of Canada Clinical Trials Group (NC...
Gespeichert in:
| Veröffentlicht in: | Journal of clinical oncology 2003-04, Vol.21 (8), p.1618-1623 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1623 |
|---|---|
| container_issue | 8 |
| container_start_page | 1618 |
| container_title | Journal of clinical oncology |
| container_volume | 21 |
| creator | Yee, Karen W L Pater, Joseph L Pho, Lam Zee, Benny Siu, Lillian L |
| description | To evaluate the enrollment of older patients (>/= 65 years) in Canadian cancer treatment trials and compare accrual of older patients in Canada and the United States.
A retrospective analysis of the number of older patients enrolled in National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) treatment trials between 1993 and 1996 was performed. These rates were compared with the corresponding rates in the general population of patients who were >/= 65 years old and had cancer, obtained from Statistics Canada, and those published by the Southwest Oncology Group (SWOG) in the United States.
Between 1993 and 1996, 4,174 patients were enrolled onto 69 NCIC CTG trials of 16 tumor types. Older patients accounted for 22% of trial enrollees, compared with 58% of the Canadian population with cancer. This discrepancy existed in all cancer types except for multiple myeloma. The percentages of older patients enrolled were also analyzed by study type: 15% in adjuvant trials, 25% in metastatic trials, 29% in investigational new drug trials, 24% in phase I trials, and 21% in supportive care trials. The overall proportion of older patients enrolled onto Canadian trials (22%) was slightly lower than that in SWOG trials (25%).
Age remains a barrier for accrual onto cancer treatment trials, even when reimbursement is not an issue. Strategies to overcome this barrier, including the implementation of trials specifically tailored to patients aged >/= 65 years, are prudent in light of our aging population. |
| doi_str_mv | 10.1200/JCO.2003.12.044 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_73190499</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>73190499</sourcerecordid><originalsourceid>FETCH-LOGICAL-c420t-7b01b21c3f99d46c253621640f22743ff5ab3b48dcb4465c2174f6ba886553f33</originalsourceid><addsrcrecordid>eNpFkU1PGzEQhq2KqgmUc2-VL_S2wd_2ckE0gtIqUnpIRW6W12sTR95dsDeq-Pd1mqCcRjN-5pX1DABfMJphgtD1r_lyViot3Qwx9gFMMSeykpLzMzBFkpIKK7qegPOctwhhpij_BCaYiFoqpaZgfd-nIcbO9SMcPFzG1iX424yhDDIMPZyb3pbRKjkz_qdWKZj4_mRacwOfNm8wZHj37KCB301KwaXbz-CjL5y7PNYL8OfhfjV_rBbLHz_nd4vKMoLGSjYINwRb6uu6ZcISTgXBgiFPiGTUe24a2jDV2oYxwS3BknnRGKUE59RTegG-HXJf0vC6c3nUXcjWxWh6N-yylhTXiNV1Aa8PoE1Dzsl5_ZJCZ9KbxkjvZeoiU-9llk4XmWXj6zF613SuPfFHewW4OgImWxN9Kq5CPnFMYimoOP1xE543f0NyOncmxhJL9NYOBGulsSiH-geY1Ic0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>73190499</pqid></control><display><type>article</type><title>Enrollment of Older Patients in Cancer Treatment Trials in Canada: Why is Age a Barrier?</title><source>MEDLINE</source><source>Journals@Ovid Complete</source><creator>Yee, Karen W L ; Pater, Joseph L ; Pho, Lam ; Zee, Benny ; Siu, Lillian L</creator><creatorcontrib>Yee, Karen W L ; Pater, Joseph L ; Pho, Lam ; Zee, Benny ; Siu, Lillian L</creatorcontrib><description>To evaluate the enrollment of older patients (>/= 65 years) in Canadian cancer treatment trials and compare accrual of older patients in Canada and the United States.
A retrospective analysis of the number of older patients enrolled in National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) treatment trials between 1993 and 1996 was performed. These rates were compared with the corresponding rates in the general population of patients who were >/= 65 years old and had cancer, obtained from Statistics Canada, and those published by the Southwest Oncology Group (SWOG) in the United States.
Between 1993 and 1996, 4,174 patients were enrolled onto 69 NCIC CTG trials of 16 tumor types. Older patients accounted for 22% of trial enrollees, compared with 58% of the Canadian population with cancer. This discrepancy existed in all cancer types except for multiple myeloma. The percentages of older patients enrolled were also analyzed by study type: 15% in adjuvant trials, 25% in metastatic trials, 29% in investigational new drug trials, 24% in phase I trials, and 21% in supportive care trials. The overall proportion of older patients enrolled onto Canadian trials (22%) was slightly lower than that in SWOG trials (25%).
Age remains a barrier for accrual onto cancer treatment trials, even when reimbursement is not an issue. Strategies to overcome this barrier, including the implementation of trials specifically tailored to patients aged >/= 65 years, are prudent in light of our aging population.</description><identifier>ISSN: 0732-183X</identifier><identifier>EISSN: 1527-7755</identifier><identifier>DOI: 10.1200/JCO.2003.12.044</identifier><identifier>PMID: 12697888</identifier><language>eng</language><publisher>Baltimore, MD: American Society of Clinical Oncology</publisher><subject>Age Factors ; Aged ; Antineoplastic agents ; Bioethics ; Biological and medical sciences ; Canada ; Chemotherapy ; Clinical Trials as Topic - statistics & numerical data ; Female ; Health Services Accessibility - statistics & numerical data ; Humans ; Male ; Medical sciences ; Neoplasms - therapy ; Patient Selection ; Pharmacology. Drug treatments ; United States</subject><ispartof>Journal of clinical oncology, 2003-04, Vol.21 (8), p.1618-1623</ispartof><rights>2003 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c420t-7b01b21c3f99d46c253621640f22743ff5ab3b48dcb4465c2174f6ba886553f33</citedby><cites>FETCH-LOGICAL-c420t-7b01b21c3f99d46c253621640f22743ff5ab3b48dcb4465c2174f6ba886553f33</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=14717636$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12697888$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yee, Karen W L</creatorcontrib><creatorcontrib>Pater, Joseph L</creatorcontrib><creatorcontrib>Pho, Lam</creatorcontrib><creatorcontrib>Zee, Benny</creatorcontrib><creatorcontrib>Siu, Lillian L</creatorcontrib><title>Enrollment of Older Patients in Cancer Treatment Trials in Canada: Why is Age a Barrier?</title><title>Journal of clinical oncology</title><addtitle>J Clin Oncol</addtitle><description>To evaluate the enrollment of older patients (>/= 65 years) in Canadian cancer treatment trials and compare accrual of older patients in Canada and the United States.
A retrospective analysis of the number of older patients enrolled in National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) treatment trials between 1993 and 1996 was performed. These rates were compared with the corresponding rates in the general population of patients who were >/= 65 years old and had cancer, obtained from Statistics Canada, and those published by the Southwest Oncology Group (SWOG) in the United States.
Between 1993 and 1996, 4,174 patients were enrolled onto 69 NCIC CTG trials of 16 tumor types. Older patients accounted for 22% of trial enrollees, compared with 58% of the Canadian population with cancer. This discrepancy existed in all cancer types except for multiple myeloma. The percentages of older patients enrolled were also analyzed by study type: 15% in adjuvant trials, 25% in metastatic trials, 29% in investigational new drug trials, 24% in phase I trials, and 21% in supportive care trials. The overall proportion of older patients enrolled onto Canadian trials (22%) was slightly lower than that in SWOG trials (25%).
Age remains a barrier for accrual onto cancer treatment trials, even when reimbursement is not an issue. Strategies to overcome this barrier, including the implementation of trials specifically tailored to patients aged >/= 65 years, are prudent in light of our aging population.</description><subject>Age Factors</subject><subject>Aged</subject><subject>Antineoplastic agents</subject><subject>Bioethics</subject><subject>Biological and medical sciences</subject><subject>Canada</subject><subject>Chemotherapy</subject><subject>Clinical Trials as Topic - statistics & numerical data</subject><subject>Female</subject><subject>Health Services Accessibility - statistics & numerical data</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Neoplasms - therapy</subject><subject>Patient Selection</subject><subject>Pharmacology. Drug treatments</subject><subject>United States</subject><issn>0732-183X</issn><issn>1527-7755</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkU1PGzEQhq2KqgmUc2-VL_S2wd_2ckE0gtIqUnpIRW6W12sTR95dsDeq-Pd1mqCcRjN-5pX1DABfMJphgtD1r_lyViot3Qwx9gFMMSeykpLzMzBFkpIKK7qegPOctwhhpij_BCaYiFoqpaZgfd-nIcbO9SMcPFzG1iX424yhDDIMPZyb3pbRKjkz_qdWKZj4_mRacwOfNm8wZHj37KCB301KwaXbz-CjL5y7PNYL8OfhfjV_rBbLHz_nd4vKMoLGSjYINwRb6uu6ZcISTgXBgiFPiGTUe24a2jDV2oYxwS3BknnRGKUE59RTegG-HXJf0vC6c3nUXcjWxWh6N-yylhTXiNV1Aa8PoE1Dzsl5_ZJCZ9KbxkjvZeoiU-9llk4XmWXj6zF613SuPfFHewW4OgImWxN9Kq5CPnFMYimoOP1xE543f0NyOncmxhJL9NYOBGulsSiH-geY1Ic0</recordid><startdate>20030415</startdate><enddate>20030415</enddate><creator>Yee, Karen W L</creator><creator>Pater, Joseph L</creator><creator>Pho, Lam</creator><creator>Zee, Benny</creator><creator>Siu, Lillian L</creator><general>American Society of Clinical Oncology</general><general>Lippincott Williams & Wilkins</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20030415</creationdate><title>Enrollment of Older Patients in Cancer Treatment Trials in Canada: Why is Age a Barrier?</title><author>Yee, Karen W L ; Pater, Joseph L ; Pho, Lam ; Zee, Benny ; Siu, Lillian L</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c420t-7b01b21c3f99d46c253621640f22743ff5ab3b48dcb4465c2174f6ba886553f33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Age Factors</topic><topic>Aged</topic><topic>Antineoplastic agents</topic><topic>Bioethics</topic><topic>Biological and medical sciences</topic><topic>Canada</topic><topic>Chemotherapy</topic><topic>Clinical Trials as Topic - statistics & numerical data</topic><topic>Female</topic><topic>Health Services Accessibility - statistics & numerical data</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Neoplasms - therapy</topic><topic>Patient Selection</topic><topic>Pharmacology. Drug treatments</topic><topic>United States</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yee, Karen W L</creatorcontrib><creatorcontrib>Pater, Joseph L</creatorcontrib><creatorcontrib>Pho, Lam</creatorcontrib><creatorcontrib>Zee, Benny</creatorcontrib><creatorcontrib>Siu, Lillian L</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of clinical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yee, Karen W L</au><au>Pater, Joseph L</au><au>Pho, Lam</au><au>Zee, Benny</au><au>Siu, Lillian L</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Enrollment of Older Patients in Cancer Treatment Trials in Canada: Why is Age a Barrier?</atitle><jtitle>Journal of clinical oncology</jtitle><addtitle>J Clin Oncol</addtitle><date>2003-04-15</date><risdate>2003</risdate><volume>21</volume><issue>8</issue><spage>1618</spage><epage>1623</epage><pages>1618-1623</pages><issn>0732-183X</issn><eissn>1527-7755</eissn><abstract>To evaluate the enrollment of older patients (>/= 65 years) in Canadian cancer treatment trials and compare accrual of older patients in Canada and the United States.
A retrospective analysis of the number of older patients enrolled in National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) treatment trials between 1993 and 1996 was performed. These rates were compared with the corresponding rates in the general population of patients who were >/= 65 years old and had cancer, obtained from Statistics Canada, and those published by the Southwest Oncology Group (SWOG) in the United States.
Between 1993 and 1996, 4,174 patients were enrolled onto 69 NCIC CTG trials of 16 tumor types. Older patients accounted for 22% of trial enrollees, compared with 58% of the Canadian population with cancer. This discrepancy existed in all cancer types except for multiple myeloma. The percentages of older patients enrolled were also analyzed by study type: 15% in adjuvant trials, 25% in metastatic trials, 29% in investigational new drug trials, 24% in phase I trials, and 21% in supportive care trials. The overall proportion of older patients enrolled onto Canadian trials (22%) was slightly lower than that in SWOG trials (25%).
Age remains a barrier for accrual onto cancer treatment trials, even when reimbursement is not an issue. Strategies to overcome this barrier, including the implementation of trials specifically tailored to patients aged >/= 65 years, are prudent in light of our aging population.</abstract><cop>Baltimore, MD</cop><pub>American Society of Clinical Oncology</pub><pmid>12697888</pmid><doi>10.1200/JCO.2003.12.044</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0732-183X |
| ispartof | Journal of clinical oncology, 2003-04, Vol.21 (8), p.1618-1623 |
| issn | 0732-183X 1527-7755 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_73190499 |
| source | MEDLINE; Journals@Ovid Complete |
| subjects | Age Factors Aged Antineoplastic agents Bioethics Biological and medical sciences Canada Chemotherapy Clinical Trials as Topic - statistics & numerical data Female Health Services Accessibility - statistics & numerical data Humans Male Medical sciences Neoplasms - therapy Patient Selection Pharmacology. Drug treatments United States |
| title | Enrollment of Older Patients in Cancer Treatment Trials in Canada: Why is Age a Barrier? |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T09%3A17%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Enrollment%20of%20Older%20Patients%20in%20Cancer%20Treatment%20Trials%20in%20Canada:%20Why%20is%20Age%20a%20Barrier?&rft.jtitle=Journal%20of%20clinical%20oncology&rft.au=Yee,%20Karen%20W%20L&rft.date=2003-04-15&rft.volume=21&rft.issue=8&rft.spage=1618&rft.epage=1623&rft.pages=1618-1623&rft.issn=0732-183X&rft.eissn=1527-7755&rft_id=info:doi/10.1200/JCO.2003.12.044&rft_dat=%3Cproquest_cross%3E73190499%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=73190499&rft_id=info:pmid/12697888&rfr_iscdi=true |